Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
暂无分享,去创建一个
A. Kimball | K. Papp | K. Gordon | C. Leonardi | Shu Li | L. T. Dooley | C. Guzzo | N. Yeilding | Yuhua Wang